Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany. The IM Cannabis news feed on Stock Titan aggregates company-issued press releases and other coverage related to its operations, strategy, governance, and capital markets activity.
Readers can expect frequent corporate updates, such as board and management changes, including appointments and departures of directors and executive officers. These announcements often detail the backgrounds of new appointees and outline how governance changes fit within the company’s broader strategic review.
The news stream also features financial reporting items, including notices about upcoming earnings releases and press releases summarizing interim financial results. These communications may discuss revenue trends, gross margin, non-IFRS measures such as Adjusted EBITDA, and commentary on factors affecting performance in Israel and Germany.
Another key category of coverage involves strategic and transactional developments. IM Cannabis has reported on initiatives to identify additional business opportunities, the signing of a non-binding term sheet to acquire a majority stake in a quantum computing bio data company, and its evaluation of potential expansion into the United States cannabis market, as well as possible divestitures of its German and Israeli operations. Capital markets updates, such as warrant amendments, resale registration statements, and Nasdaq listing compliance notices, are also part of the company’s news flow.
For investors and observers tracking IMCC, this page offers a centralized view of how the company communicates its progress in medical cannabis markets, its strategic review, and its responses to regulatory and market conditions. Users who follow IM Cannabis can use this news feed to monitor developments over time and review the company’s own descriptions of its plans and performance.
IM Cannabis (Nasdaq: IMCC) raised US$2,171,660.40 via two arm's‑length note financings announced Jan 26, 2026.
The First Note (issued Jan 7, 2026) has principal US$1,538,749 after a 10% issuance discount, 8% interest (rises to 14% on default), 18‑month maturity with lender extension option, conversion at the lower of US$1.47 or 90% of 20‑day low VWAP (floor US$0.29), and 228,150 five‑year warrants at C$3.45. The Second Note (issued Jan 20, 2026) has principal US$632,911.50 after 10% discount, identical interest and maturity terms, conversion at the lower of US$1.38 or 90% of 20‑day low VWAP (floor US$0.275), and 93,671 five‑year warrants at C$3.45.
Approximately US$500,000 of proceeds were used to repay existing creditors; the company agreed to file an F-3 registration within 30 trading days. All securities are subject to a four‑month and one‑day hold.
IM Cannabis (Nasdaq: IMCC) announced the appointment of Alon Dayan to its board of directors effective December 31, 2025. The company operates in Israel and Germany and named Dayan for his executive experience in homeland security technology and systems integration.
Dayan is CEO of KeepZone AI since 2025 and founder/CEO of L1-Systems since 2014, where he led projects in homeland security, intelligence systems and telecommunications across Latin America, Eastern Europe, and Western Europe. His prior roles include CEO of Virtual Crypto Technologies and business development at Elbit Systems. He holds a B.A. in Electrical and Electronic Engineering from Ariel University.
IM Cannabis (Nasdaq: IMCC) announced on Dec 30, 2025 that it is evaluating strategic options to enter the U.S. cannabis market after President Trump's Dec 18, 2025 executive order directing rescheduling of marijuana toward Schedule III. The company engaged SSC Advisors to provide financial advisory services to support potential U.S. market entry, identify partners or acquirors, and manage transaction processes related to its German and Israeli operations. IM Cannabis said it will continue monitoring federal rescheduling developments as it assesses possible divestitures and U.S. expansion opportunities.
IM Cannabis (Nasdaq: IMCC) appointed Asi Levi, CPA as Chief Financial Officer effective December 12, 2025, replacing Uri Birenberg.
Mr. Levi has over 15 years of finance experience, including prior CFO roles at Water Ways Technologies and DekelOil CI and controller roles at SciSparc and A2Z Cust2Mate. The company said he oversaw fundraising, financial planning, budgeting and cash flow management under IFRS and other standards. The company thanked Mr. Birenberg for his service and wished him success in future endeavors.
IM Cannabis (NASDAQ: IMCC) reported Q3 2025 results for the quarter and nine months ended September 30, 2025, with amounts in Canadian dollars.
Key Q3 2025 figures: Revenue $13.9M (flat vs. Q3 2024), Gross profit $2.7M (down 13%), Gross margin 20% (from 23%), One-time goodwill and intangible impairment $3.1M, Operating expenses $6.9M (up 68%), and Net loss $3.9M. Non-IFRS Adjusted EBITDA loss was $0.6M. Cash and restricted cash totaled $2.3M as of September 30, 2025. Total assets rose to $44.3M and total liabilities to $40.0M. The company included a going concern note and cited possible regulatory headwinds in Germany and strategic review activities.
IM Cannabis (NASDAQ: IMCC) will report operational and financial results for the third quarter 2025, which ended September 30, 2025.
The company said results will be released on Thursday, November 13, 2025, before the market opens. IM Cannabis operates in Israel and Germany.
IM Cannabis (NASDAQ: IMCC) announced that Chief Financial Officer Uri Birenberg will step down for personal reasons, remaining in the role through January 5, 2026 or an earlier date as determined by the company.
Mr. Birenberg will assist in a structured transition until a successor is appointed. The company noted his two-year tenure and the CEO expressed thanks for his contributions.
IM Cannabis (NASDAQ: IMCC) announced on Oct 23, 2025 a non-binding term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million.
Consideration may include cash, IMC shares and performance-linked earn-outs. The deal is subject to due diligence, definitive agreements, corporate and regulatory approvals, and customary closing conditions, and may not be completed as proposed. The move follows IMC's exploration of additional business activities to enhance long-term growth and shareholder value.
IM Cannabis (NASDAQ:IMCC), a medical cannabis company operating in Israel and Germany, announced significant changes to its Board of Directors effective September 15, 2025. The company appointed Asaf Yitzhaik and Eli Zamir to replace departing board members Shmulik Arbel and Brian Schinderle.
Oz Adler has been appointed as the new Chairman of the Board, replacing Oren Shuster, who continues as CEO and director. The new board members bring extensive experience in retail, real estate, finance, and capital markets. Additionally, the company announced plans to explore new business opportunities to enhance growth and shareholder value.
IM Cannabis (NASDAQ: IMCC), a medical cannabis company operating in Israel and Germany, has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq on September 4, 2025 that it now meets the minimum stockholders' equity requirement of $2.5 million under Rule 5550(b)(1). As a result, IMCC's common stock will maintain its listing and continue trading on the Nasdaq Capital Market.
FAQ
What is the current stock price of Im Cannabis (IMCC)?
What is the market cap of Im Cannabis (IMCC)?
